Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABO2102
- Development stage
- Phase 1
- Lead developer
- Abogen Bioscience
- Modality
- mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ABO2102 is an investigational mRNA vaccine designed to encode mutant KRAS neoantigens. It is being developed for the treatment of cancers harboring KRAS mutations, with a primary focus on advanced pancreatic cancer. The vaccine aims to stimulate an immune response against tumor cells expressing specific KRAS mutations by delivering mRNA encoding these neoantigens intramuscularly. Clinical trials are evaluating its safety, immunogenicity, pharmacodynamics, and preliminary anti-tumor activity both as monotherapy and in combination with toripalimab (an anti-PD-1 monoclonal antibody). The developer is Suzhou Abogen Biosciences[1][2][3][5].
- Other names
- KRAS Neoantigen mRNA Vaccine
02
Targets
Kirsten rat sarcoma viral oncogene homolog mutated protein
Beyond the preview
Go deeper on ABO2102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABO2102.